Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.

The Journal of clinical endocrinology and metabolism - 1 Jan 2010

Bernabeu Ignacio, Alvarez-Escolá Cristina, Quinteiro Celsa, Lucas Tomás, Puig-Domingo Manel, Luque-Ramírez Manuel, de Miguel-Novoa Paz, Fernandez-Rodriguez Eva, Halperin Irene, Loidi Lourdes, Casanueva Felipe F, Marazuela Mónica

Abstract excerpt

CONTEXT: The deletion of exon 3 in the GH receptor (GHR) has been associated with a different biochemical picture and response to therapy in acromegaly. OBJECTIVE: The aim of the study was to determine whether or not the GHR genotype influences the efficacy of pegvisomant treatment. DESIGN AND SETTING: A cross-sectional study was conducted in six Spanish university hospitals. PATIENTS: Forty-four acromegalic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acromegaly
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Resistance

Share to Human Growth Hormone

Share to Mutant Proteins

Share to Receptors, Somatotropin

Share to Sequence Deletion

Source

Identifiers

PMID: 19850678
DOI: 10.1210/jc.2009-1630

Genes

GHR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.PMID 19850678Read ↗

Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.Semantic proximity Read ↗

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3Semantic proximity Read ↗

Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.Semantic proximity Read ↗

Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.Semantic proximity Read ↗

Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.Semantic proximity Read ↗

d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.Semantic proximity Read ↗

The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.Semantic proximity Read ↗

The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly.Semantic proximity Read ↗

The Exon 3-Deleted Growth Hormone Receptor (d3GHR) Polymorphism - a Favorable Backdoor Mechanism for the GHR FunctionSemantic proximity Read ↗

D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly.Semantic proximity Read ↗

Genetic Predictors of Response to Different Medical Therapies in Acromegaly.Semantic proximity Read ↗

Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with AcromegalySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.